Scaling-up treatment for HIV/AIDS: Lessons learned from multidrug-resistant tuberculosis

Lancet

Volumn 363, Issue 9405, 2004, Pages 320-324

  Gupta, Rajesh ^a   Irwin, Alexander ^a   Raviglione, Mario C ^a   Kim, Jim Yong ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG USE; HEALTH CARE; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; UNITED NATIONS; WORLD HEALTH ORGANIZATION;

EID: 0942278953     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)15394-9     Document Type: Article

References (37)

1. WHO. World Health Organization says failure to deliver AIDS medicines is a global health emergency. http://www.who.int/mediacentre/releases/2003/pr67/en/ (accessed Nov 8, 2003).
2. World Health Organization and Joint United Nations Programme on HIV/AIDS. Treating 3 Million by 2005: making it happen, the WHO Strategy. Geneva, WHO 2003.
3. Geerligs W.A., van Altena R., Lange W.C.M., van Soolingen D., van der Werf T.S. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis. 4:2000;758-764.
4. Flament-Saillour M., Robert J., Jarlier V., Grosset J. Outcome of multidrug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med. 160:1999;587-593.
5. Telzak E.E., Sepkowitz K., Alpert P., et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med. 333:1995;907-911.
6. Narita M., Alonso P., Lauzardo M., Hollender E.S., Pitchenik A.E., Ashkin D. Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-97. Chest. 120:2001;343-348.
7. Viskum K., Kok-Jensen A. Multidrug-resistant tuberculosis in Denmark. Int J Tuberc Lung Dis. 1:1997;299-301.
8. Park S.K., Kim C.T., Song S.D. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. Int J Tuberc Lung Dis. 2:1998;877-884.
9. Treatment of Tuberculosis: guidelines for national programmes. 2nd edn :1997;World Health Organization, Geneva.
10. Enarson D.A., Rieder H.L., Arnadottir T., Trebucq A. Management of tuberculosis: a guide for low income countries. 2000;International Union Against Tuberculosis and Lung Disease, Paris.
11. Guidelines for the management of drug-resistant tuberculosis. 1997;World Health Organization, Geneva.
12. Gupta R., Kim J.Y., Espinal M.A., et al. Responding to market failures in tuberculosis control. Science. 293:2001;1048-1051.
13. Arnadottir T, Gupta R, eds. Guidelines for establishing DOTS-plus pilot projects for the management of multidrug-resistant tuberculosis. Geneva: World Health Organization, 2001.
14. Cullinan T. Drug-resistant tuberculosis: desperate measures? Lancet. 357:2001;1124.
15. Gupta R., Cegielski J.P., Espinal M.A., et al. Increasing transparency in partnerships for health-introducing the Green Light Committee. Trop Med Int Health. 7:2002;970-976.
16. Mitnick C., Bayona J., Palacios E., et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 348:2003;119-128.
17. Riekstina V., Leimane V., Zarovska E., Holtz T.H., Wells C. Outcome of multidrug-resistant tuberculosis treatment in patients given individualised therapy, Latvia, 2000. Int J Tuberc Lung Dis. 7:2003;S204.
18. World Health Organization. Rreport of the meeting of the stop TB working group on DOTS-plus for MDR-TB. 27-28 October, 2003. In preparation.
19. Suarez P.G., Floyd K., Portocarrero J., et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet. 359:2002;1980-1989.
20. Gupta R., Raviglione M.C., Espinal M.A. Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)? Int J Tuberc Lung Dis. 5:2001;1078-1079.
21. Kim J.Y., Mukherjee J.S., Rich M.L., Mate K., Bayona J., Becerra M.C. From multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift. Tuberculosis. 83:2003;59-65.
22. Gupta R., Espinal M., Raviglione M.C. Evidence and uncertainties. Int J Tuberc Lung Dis. 6:2002;651-653.
23. Gupta R, Espinal M, on behalf of the Stop TB Working Group on DOTS-Plus for MDR-TB. A prioritised research agenda for DOTS-plus for multidrug-resistant tuberculosis (MDR-TB). Int J Tuberc Lung Dis 2003; 7: 410-14.
24. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. 2002;World Health Organization, Geneva.
25. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach: 2003 revision. 2003;World Health Organization, Geneva.
26. Mukherjee J., Farmer P., Leandre F., et al. Access to antiretroviral treatment and care: the experience of the HIV equity initiative, Cange, Haiti. 2003;World Health Organization, Geneva.
27. Okero A., Aceng E., Madraa E., Namagala E., Serutoke J. Scaling up antiretroviral therapy: experience in Uganda. 2003;World Health Organization, Geneva.
28. Médecins Sans Frontières - South Africa, Department of Public Health at the University of Cape Town, and the Provincial Administration of the Western Cape, South Africa. Antiretroviral therapy in primary health care: experience of Khayelitsha programme in South Africa. Geneva: World Health Organization, 2003.
29. Rabkin M., El-Sadr W.M. Saving mothers, saving families: the MCTC-Plus initiative. 2003;World Health Organization, Geneva.
30. Rabkin M., El-Sadr W., Katzenstein D.A., et al. Antriretroviral treatment in resource-poor settings: clinical research priorities. Lancet. 360:2002;1503-1505.
31. Zimmerman R. Eli Lilly, Health Officials join to fight tuberculosis. Wall Street Journal June 5, 2003.
32. Friedman M.A., den Besten H., Attaran A. Out-licensing: a practical approach for improvement of access to medicines in poor countries. Lancet. 361:2003;341-344.
33. Freeman P. Pan American Health Organization's s revolving fund: children vaccine commission working paper, 1999. 1999;Children Vaccine Commission, Geneva.
34. WHO. Prequalification project. http://mednet3.who.int/prequal/default. shtml (accessed Jan 12, 2004).
35. Mukherjee J.S., Farmer P.E., Niyizonkiza D., et al. Tackling HIV in resource poor countries. BMJ. 327:2003;1104-1106.
36. Farmer P., Leandre F., Mukherjee J.S., et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet. 358:2001;404-409.
37. Lee J.W. Global health improvement and WHO: shaping the future. Lancet. 362:2003;2083-2088.